



Contribution ID: 1117

Type: SPA

Development of ^{211}At -Radiopharmaceuticals for Pretargeted Radioimmunotherapy of Disseminated Cancer

Tuesday, 17 May 2022 16:35 (5 minutes)

To enhance the therapeutic efficacy of radioimmunotherapy of cancer, several pretargeting strategies have been developed. In pretargeted radioimmunotherapy, the tumour is pretargeted with a modified monoclonal antibody that has affinity for both, tumour antigen and radiolabeled carrier. A big challenge in cancer treatment is the elimination of occult disseminated tumour cells, in this context the alpha emitter ^{211}At has drawn attention due to its physicochemical characteristics. This project aims to design new molecules for pretargeting applications based on the Diels Alder click chemistry system (Tetrazine (Tz)/Trans-cyclooctene (Tco)) using ^{211}At as radionuclide, and to evaluate these substances to optimize the pharmacokinetics.

Presenter: TIMPERANZA, Chiara (University of Gothenburg)

Session Classification: Student Poster Appetizers